Serum endostatin levels in patients with metastatic and non-metastatic well-differentiated thyroid cancer

Endokrynologia Polska

Volumn 61, Issue 1, 2010, Pages 7-12

  Kłubo Gwieździnska, Joanna ^a   Junik, Roman ^a   Kopczyńska, Ewa ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

Endostatin; Metastases; Thyroid cancer; TSH stimulation

Indexed keywords

ENDOSTATIN; THYROTROPIN;

ADULT; ARTICLE; CANCER REGRESSION; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; HORMONAL REGULATION; HUMAN; HUMAN TISSUE; LOCOREGIONAL METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; PROTEIN BLOOD LEVEL; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA;

ADENOCARCINOMA, FOLLICULAR; ADENOCARCINOMA, PAPILLARY; ADULT; CROSS-SECTIONAL STUDIES; ENDOSTATINS; FEMALE; HUMANS; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; REFERENCE VALUES; THYROID NEOPLASMS; THYROTROPIN;

EID: 77950523627     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Folkman J. Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action. Exp Cell Res 2006; 312:594-607. (Pubitemid 43290336)
2. Abdollahi A, Hahnfeldt P, Maercker C et al. Endostatin's anriangiogenic signaling network. Mol Cell 2004; 13:649-663.
3. Abdollahi A, Matky L, Huber PE. Endostatin: the logic of anriangiogenic therapy. Drug Resist Updat 2005; 8:59-74.
4. Sun Y, Wang J, Liu Yet al. Results of phase HI trial of rh-endostatin (YH-16) in advanced non-small cell lung cancer (NSCLC) patients. J Clin Oncol 2005; 23:138 (Abstract).
5. Hoffmann S, Wunderlich A, Lingelbach S et al. Expression and secretion of endostatin in thyroid cancer. Ann Surg Oncol 2008; 15: 3601-3608.
6. Ye C, Feng C, Wang S et al. Anriangiogenic and antitumor effects of endostatin on follicular thyroid carcinoma. Endocrinology 2002; 143: 3522-3528. (Pubitemid 34925727)
7. Woo IS, Kim KA, Jeon HM et al. Pre treatment serum endostatin as a prognostic indicator in metastatic gastric carcinoma. Int J Cancer 2006; 119: 2901-2906.
8. Hu TH, Huang CC, Wu CL et al. Increased endostatin/collagen XVIII expression correlates with elevated VEGF level and poor prognosis in hepatocellular carcinoma. Mod Pathol 2005; 18:663-672.
9. Feldman AL, Alexander HR Jr, Yang JC et al. Prospective analysis of circulating endostatin levels in patients with renal cell carcinoma. Cancer 2002; 95:1637-1643.
10. Bono P, Teerenhovi L, Joensuu H. Elevated serum endostatin is associated with poor outcome in patients with non-Hodgkin lymphoma. Cancer 2003; 97:2767-2775. (Pubitemid 36605144)
11. Iizasa T, Chang H, Suzuki M et al. Overexpression of collagen XVIII is associated with poor outcome and elevated levels of circulating serum endostatin in non-small cell lung cancer. Clin Cancer Res 2004; 10: 5361-5366. (Pubitemid 39100472)
12. Tjin Tham Sjin RM, Naspinski J et al. Endostatin therapy reveals a U-shaped curve for antitumor activity. Cancer Gene Ther 2006; 13:619-627. (Pubitemid 43756250)
13. Celik I, Sürücü O, Dietz C et al. Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve. Cancer Res 2005; 65:11044- -11050. (Pubitemid 41713375)
14. Klubo-Gwiezdzinska J, Junik R, Kopczyńska E et al. The comparison of serum vascular endothelial growth factor levels between patients with metastatic and non-metastatic thyroid cancer, and patients with nontoxic multinodular goiter. Eur I Endocrinol 2007; 157:521-527. (Pubitemid 350018457)
15. Tuttle RM, Fleisher M, Francis GL et al. Serum vascular endothelial growth factor levels are elevated in metastatic differentiated thyroid cancer but not increased by short-term TSH stimulation. J Clin Endocrinol Metab 2002; 87:1737-1742. (Pubitemid 34615263)
16. Sorvillo F, MazziotrJ G, Carbone A et al. Recombinant human thyrotropin reduces serum vascular endothelial growth factor levels in patients monitored for thyroid carcinoma even in the absence of thyroid tissue. J Clin Endocrinol Metab 2003; 88:4818-4822. (Pubitemid 37357531)
17. Feldman AL, Alexander HR Jr, Bartlett DL et al. A prospective analysis of plasma endostatin levels in colorectal cancer patients with liver metastases. Ann Surg Oncol 2001; 8:741-745.
18. Feldman AL, Tamarkin L, Pariotti GF et al. Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV dear cell renal cancer. Clin Cancer Res 2000; 6:4628-14234 (Pubitemid 32110397)
19. Zhao J, Yan F, Ju H et al. Correlation between serum vascular endothelial growth factor and endostatin levels in patients with breast cancer. Cancer Lett. 2004; 204:87-95. (Pubitemid 38117197)
20. Sorisky A, Bell A, Gagnon A. TSH receptor in adipose cells. Hormone and Metabolic Research 2000; 32:468-474. (Pubitemid 32176073)
21. Davis FB, Mousa SA, O'Connor L et al. Proangiogenic action of thyroid hormone is fibroblast growth factor-dependent and is initiated at the cell surface. Circ Res 2004; 94:1500-1506. (Pubitemid 38780323)
22. Mousa SA, Davis FB, Mohamed S et al. Proangiogenesis action of thyroid hormone and analogs in a three-dimensional in vitro microvascular endothelial sprouting model. Int Angiol 2006; 25:407-413. (Pubitemid 46351000)
23. Reda M, Zickri M. Thyroxine as a stimulator of liver regeneration after partial hepatectomy:an experimental animal study. J Egypt Soc Parasitol 2008; 38:853-S61.
24. Jiang JY, Miyabayashi K, Nottola SA et al Thyroxine treatment stimulated ovarian follicular angiogenesis in immature hypothyroid rats. Histol Histopatho 2008; 23:1387-1798.
25. Bergh JJ, Lin HY, Lansing L et al. Integrin alpha Vbeta3 contains a cell surface receptor site for thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis. Endocrinology 2005; 146:2864-2871. (Pubitemid 41002793)
26. Dedecjus M, Kolomecki K, Brzeziński J et al. Influence of L-thyroxine administration on poor-platelet plasma VEGF concentrations in patients with induced short-term hypothyroidism, monitored for thyroid carcinoma. Endocr J 2007; 54:63-69. (Pubitemid 46481673)
27. Kucharz EJ, Kotulska A, Kope? M et al. Serum level of the circulating angiogenesis inhibitor endostatin in patients with hyperthyroidism or hypothyroidism. Wien Klin Wochenschr 115; 2003:179-181. (Pubitemid 36457120)